Initiates Coverage on Kamada (NASDAQ:KMDA)

Analysts at initiated coverage on shares of Kamada (NASDAQ:KMDAGet Free Report) in a research note issued on Tuesday. The brokerage set a “buy” rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Kamada in a research note on Thursday, May 9th.

Check Out Our Latest Report on Kamada

Kamada Stock Performance

KMDA opened at $5.25 on Tuesday. The firm has a market cap of $301.77 million, a P/E ratio of 22.83 and a beta of 1.06. The business has a 50 day moving average price of $5.33 and a 200 day moving average price of $5.64. Kamada has a twelve month low of $4.08 and a twelve month high of $6.53.

Kamada (NASDAQ:KMDAGet Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.02). Kamada had a return on equity of 5.50% and a net margin of 8.33%. The firm had revenue of $37.74 million for the quarter, compared to the consensus estimate of $38.01 million. As a group, analysts anticipate that Kamada will post 0.26 earnings per share for the current fiscal year.

Institutional Trading of Kamada

A number of hedge funds have recently bought and sold shares of KMDA. EWA LLC bought a new position in shares of Kamada during the 4th quarter worth about $68,000. Y.D. More Investments Ltd raised its holdings in Kamada by 107.1% in the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 15,000 shares in the last quarter. Aristides Capital LLC lifted its position in shares of Kamada by 41.6% in the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after acquiring an additional 16,635 shares during the period. Calton & Associates Inc. bought a new stake in shares of Kamada in the 4th quarter worth approximately $111,000. Finally, Vanguard Group Inc. grew its holdings in shares of Kamada by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after purchasing an additional 100,800 shares in the last quarter. 20.38% of the stock is owned by institutional investors.

Kamada Company Profile

(Get Free Report)

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

Read More

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with's FREE daily email newsletter.